Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

  • Clinical Trial Report
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

An Erratum to this article was published on 30 March 2011

Abstract

Background

Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients.

Methods

Patients with progressive CRPC, pretreated with docetaxel, were enrolled at the Department of Molecular and Clinical Oncology and Endocrinology of University ‘Federico II of Naples’ from April 2007 to January 2010. Accrued patients received cisplatin at the dose of 75 mg/m2 every 3 weeks with daily 10 mg prednisone. Measures of response and progression were defined according to the Prostate Cancer Working Group (PCWG1) criteria. Toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute, version 3.0.

Results

Twenty-five patients were recruited. Median age was 65 years (interquartile range 55–74 years). All patients were evaluable for PSA response and toxicity and thirteen patients (52%) were evaluable for measurable disease. A total of 170 cycles of cisplatin chemotherapy were administered. Median dose intensity corresponded to 96% (range 83.8–98.3%) of the maximum dose intensity that could be delivered. Three patients (12%) presented grade 3–4 neuropathy and ten (40%) presented grade 3–4 neutropenia. Five patients (20%) showed a greater than 50% PSA decline, and three of thirteen patients with measurable disease presented a partial response. Median progression-free survival was 5.6 months (24 weeks; range 15–24). Median survival was 55 weeks (range 46–64; see Fig. 1).

Conclusions

Cisplatin plus prednisone appears to represent an active regimen in docetaxel-refractory CRPC with an acceptable toxicity profile. Further investigations in this setting are warranted to confirm these early encouraging findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  2. Di Lorenzo G, Autorino R, Figg WD, De Placido S (2007) Hormone-refractory prostate cancer: where are we going? Drugs 67:1109–1124

    Article  PubMed  CAS  Google Scholar 

  3. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN (2010) Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 70:983–1000

    Article  PubMed  CAS  Google Scholar 

  4. Di Lorenzo G, Buonerba C, Faiella A et al (2010) Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int [Epub ahead of print]

  5. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  PubMed  CAS  Google Scholar 

  6. De Bono JS, Logothetis CJ, Fizazi K et al (2010) Abiraterone acetate plus low dose prednisone improves overall survival in patients (pts) with metastatic castration resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Ann Oncol 21:viii1–viii12

    Google Scholar 

  7. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  PubMed  Google Scholar 

  8. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159

    Article  PubMed  Google Scholar 

  9. Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461–3467

    PubMed  CAS  Google Scholar 

  10. Ning YM, Gulley JL, Arlen PM et al (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:2070–2076

    Article  PubMed  CAS  Google Scholar 

  11. Danila DC, Morris MJ, de Bono JS et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496–1501

    Article  PubMed  CAS  Google Scholar 

  12. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109

    Article  PubMed  CAS  Google Scholar 

  13. Loriot Y, Massard C, Gross-Goupil M et al (2009) Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 20:703–708

    Article  PubMed  CAS  Google Scholar 

  14. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  15. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F (2004) Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 150:299–303

    Article  PubMed  CAS  Google Scholar 

  16. Di Lorenzo G, Autorino R, Perdonà S et al (2007) Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol 52:1020–1027

    Article  PubMed  CAS  Google Scholar 

  17. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–13

    Article  PubMed  CAS  Google Scholar 

  18. Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 106:1041–1046

    Article  PubMed  CAS  Google Scholar 

  19. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122–130

    PubMed  CAS  Google Scholar 

  20. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422

    PubMed  CAS  Google Scholar 

  21. Greenberg D, Earle C, Fang C-H, Eldar-Lissai A, Neumann PJ (2010) When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 102:82–88

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

CB wishes to dedicate this work to his loving mother, the late prof. Mariarosaria Napoletano, who kept encouraging him to complete the writing of this paper during the last weeks of her life.

Conflict of interest

None to declare.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Naples, Italy

    Carlo Buonerba, Piera Federico, Carmine D’Aniello, Pasquale Rescigno, Carla Cavaliere, Livio Puglia, Matteo Ferro, Vincenzo Altieri, Sisto Perdonà, Sabino De Placido & Giuseppe Di Lorenzo

Authors
  1. Carlo Buonerba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piera Federico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carmine D’Aniello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pasquale Rescigno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carla Cavaliere
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Livio Puglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matteo Ferro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vincenzo Altieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sisto Perdonà
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sabino De Placido
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Giuseppe Di Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Di Lorenzo.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00280-011-1626-8

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buonerba, C., Federico, P., D’Aniello, C. et al. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemother Pharmacol 67, 1455–1461 (2011). https://doi.org/10.1007/s00280-011-1594-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1594-z

Keywords

Search

Navigation